6. Bibliografía

-Loureiro JB, Ribeiro R, Nazareth N, Ferreira T, Lopes EA, Gama A, Machuqueiro M, Alves MG, Marabini L, Oliveira PA, Santos MMM, Saraiva L. Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis. Pharmacol Res. 2022; 175:106026.

–Mohania D, Chandel S, Kumar P, Verma V, Digvijay K, Tripathi D, Choudhury K, Mitten SK, Shah D. Ultraviolet Radiations: Skin Defense-Damage Mechanism. Adv Exp Med Biol. 2017; 996:71-87.

-Willenbrink TJ, Ruiz ES, Cornejo CM, Schmults CD, Arron ST, Jambusaria-Pahlajani A. Field cancerization: Definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol. 2020; 83(3):709-717.

-García-de-la-Fuente MR. Carcinoma basocelular: estudio del origen, transición epitelio mesénquima, inmunidad y regresión. Tesis doctoral, Universidad de Lleida, 2017.

-Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012; 166:1069‐1080.

-Revenga Arranz F, Paricio Rubio JF, Mar Vázquez Salvado M, del Villar Sordo V. Descriptive epidemiology of basal cell carcinoma and cutaneous squamous cell carcinoma in Soria (north-eastern Spain) 1998-2000: a hospital-based survey. J Eur Acad Dermatol Venereol. 2004; 18:137‐141.

-Pfeifer GP, Besaratinia A. UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer. Photochem Photobiol Sci. 2012; 11:90‐97.

-Gordon LG, Elliott TM, Olsen CM, Pandeya N, Whiteman DC. Multiplicity of skin cancers in Queensland and their cost burden to government and patients. Aust N Z J Public Health. 2018; 42:86‐91.

-Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur J Cancer Prev. 2015; 24:141‐149.

-Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest. 2012; 122:464-472.

-Figueras Nart I, Cerio R, Dirschka T, Dréno B, Lear JT, Pellacani G, Peris K, Ruiz de Casas A. Progressing Evidence in AK (PEAK) Working Group. Defining the actinic keratosis field: a literature review and discussion. J Eur Acad Dermatol Venereol. 2018; 32:544-563.

-Green AC. Epidemiology of actinic keratoses. Curr Probl Dermatol. 2015; 46:1-7.

-Lai V, Cranwell W, Sinclair R. Epidemiology of skin cancer in the mature patient. Clin Dermatol. 2018; 36:167-176.

-Ko CJ, Cj K. Actinic keratosis: facts and controversies. Clin Dermatol. 2010; 28:249-253.

-Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2017; 177:350-358.

-Fernandez-Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017; 31(Suppl 2):5-7.

-Jetter N, Chandan N, Wang S, Tsoukas M. Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review. Am J Clin Dermatol. 2018; 19:543-557.

-Reinehr CPH, Bakos RM. Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects. An Bras Dermatol. 2019; 94(6):637-657.

–Ciudad C, Avilés JA, Suárez R, Lázaro P. Utilidad de la dermatoscopia en el diagnóstico de las queratosis actínicas pigmentadas. Actas Dermosifiliogr. 2011; 102(8):623-6.

–Pereyra-Rodriguez JJ, Monserrat-García MT, Corbí-Llopis R, Conejo-Mir Sánchez J. Determinantes del tratamiento de las queratosis actínicas por médicos de atención primaria. Actas Dermosifiliogr. 2020; S0001-7310(20)30083-1.

–Ferrándiz C, Fonseca-Capdevila E, García-Diez A, Guillén-Barona C, Belinchón-Romero I, Redondo-Bellón P, Moreno-Giménez JC, Senán R. Spanish adaptation of the European guidelines for the evaluation and treatment of actinic keratosis. Actas Dermosifiliogr. 2014; 105:378‐393.

-Steeb T, Wessely A, von Bubnoff D, Dirschka T, Drexler K, Falkenberg C, Hassel JC, Hayani K, Hüning S, Kähler KC, Karrer S, Krammer C, Leiter U, Lill D, Marsela E, Meiwes A, Nashan D, Nasifoglu S, Schmitz L, Sirokay J, Thiem A, Utikal J, Zink A, Berking C, Heppt MV. Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. J Clin Med. 2020; 9:E1438.

-Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther. 2015; 5:19-35.

-Ceilley RI. Mechanisms of action of topical 5-fluorouracil: Review and implications for the treatment of dermatological disorders. J Dermatolog Treat 2012; 23:83-9.

-Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011; 165:1101-8.

-Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiquimod 5% cream. Br J Dermatol. 2003;149 Suppl 66:37-9.

-Quist SR, Gollnick HP. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses. Expert Opin Pharmacother 2011; 12:451-61.

-Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366:1010-9.

-Segura S, Gadea A, Nonell L, et al. Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel. PLoS One. 2020;15:e0232146.

-Maltusch A, Röwert-Huber J, Matthies C, Lange-Asschenfeldt S, Stockfleth E. Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis. J Dtsch Dermatol Ges. 2011; 9:1011-7.

-Batra R, Sundararajan S, Sandramouli S. Topical diclofenac gel for the management of periocular actinic keratosis. Ophthal Plast Reconstr Surg. 2012; 28:1-3.

-Wójcicka K, Szepietowski JC. Surgical approach to the management of field cancerization: Own experience. Dermatol Ther. 2020; 33(4):e13621.

–de Oliveira MC, Trevisan F, Pinto CA, Xavier CA, Pinto JC. Histopathological analysis of the therapeutic response to cryotherapy with liquid nitrogen in patients with multiple actinic keratosis. An Bras Dermatol. 2015; 90(3):384-9.

-Richard MA, Amici JM, Basset-Seguin N, Claudel JP, Cribier B, Dreno B. Management of actinic keratosis at specific body sites in patients at high risk of carcinoma lesions: expert consensus from the AKTeam™ of expert clinicians. J Eur Acad Dermatol Venereol. 2018; 32:339-346.

–Bernal Masferrer L, Gracia Cazaña T, Bernad Alonso I, Álvarez-Salafranca M, Almenara Blasco M, Gallego Rentero M, Juarranz de la Fuente Á, Gilaberte Y. Topical Immunotherapy for Actinic Keratosis and Field Cancerization. Cancers (Basel). 2024; 16(6):1133.

-Rodríguez-Blanco I, Flórez Á, Paredes-Suárez C, Rodríguez-Lojo R, González-Vilas D, Ramírez-Santos A, Paradela S, Suárez Conde I, Pereiro-Ferreirós M. Actinic Cheilitis Prevalence and Risk Factors: A Cross-sectional, Multicentre Study in a Population Aged 45 Years and Over in North-west Spain. Acta Derm Venereol. 2018; 98:970-974.

-Lugović-Mihić L, Pilipović K, Crnarić I, Šitum M, Duvančić T. Differential Diagnosis of Cheilitis – How to Classify Cheilitis? Acta Clin Croat. 2018; 57:342-351.

-Rossini RC, Dellatorre G, Mesquita LAF, Tarlé RG. Ingenol mebutate treatment for actinic cheilitis: clinical, histopathological and p53 profile of 14 cases. J Dermatolog Treat. 2020 Feb 27:1-4.

-Andreadis D, Pavlou A, Vakirlis E, Anagnostou E, Vrani F, Poulopoulos A, Kolokotronis A, Ioannidis D, Sotiriou E. Daylight photodynamic therapy for the management of actinic cheilitis. Arch Dermatol Res. 2020. doi: 10.1007/s00403-020-02069-y.

-Chang SH, Huang ZS, Chen WL, Zhou B, Zhong JL. Vermilionectomy followed by reconstruction of the vermilion mucosa using allograft dermal matrix in patients with actinic cheilitis of the lower lip. J Cosmet Dermatol. 2020. doi: 10.1111/jocd.13473.

-Varela-Centelles P, Seoane-Romero J, García-Pola MJ, Leira-Feijoo Y, Seoane-Romero JM. Therapeutic approaches for actinic cheilitis: therapeutic efficacy and malignant transformation after treatment. Int J Oral Maxillofac Surg. 2020: S0901-5027(20)30082-5.

-Salgueiro AP, de Jesus LH, de Souza IF, Rados PV, Visioli F. Treatment of actinic cheilitis: a systematic review. Clin Oral Investig. 2019; 23:2041-2053.

-Lai M, Pampena R, Cornacchia L, Pellacani G, Peris K, Longo C. Treatments of actinic cheilitis: A systematic review of the literature. J Am Acad Dermatol. 2019:S0190-9622(19)32501-0.

–van der Waal I. Oral leukoplakia, the ongoing discussion on definition and terminology. Med Oral Patol Oral Cir Bucal. 2015; 20:e685-92.

-Khan A, Ongole R, Baptist J, Srikant N, Lukmani F. Patterns of Tobacco Use and its Relation to Oral Precancers and Cancers among Individuals Visiting a Tertiary Hospital in South India. J Contemp Dent Pract. 2020; 21:304-309.

-Foki E, Gangl K, Kranebitter V, Niederberger-Leppin V, Eckl-Dorna J, Wiebringhaus R, Thurnher D, Heiduschka G. Early effects of cigarette smoke extract on human oral keratinocytes and carcinogenesis in head and neck squamous cell carcinoma. Head Neck. 2020. doi: 10.1002/hed.26247.

-Bewley AF, Farwell DG. Oral leukoplakia and oral cavity squamous cell carcinoma. Clin Dermatol. 2017; 35:461-467.

-Jayasooriya PR, Dayaratne K, Dissanayake UB, Warnakulasuriya S. Malignant transformation of oral leukoplakia: a follow-up study. Clin Oral Investig. 2020; doi: 10.1007/s00784-020-03322-4).

-Villa A, Woo SB. Leukoplakia-A Diagnostic and Management Algorithm. J Oral Maxillofac Surg. 2017; 75:723-734.

-De Falco D, Di Venere D, Maiorano E. Diode Laser Surgery of Recurrent White Lesion of the Lip: Clinicopathological Consideration and Cosmetic Outcome. Cureus. 2020; 12:e7585.

-Holmstrup P, Dabelsteen E. Oral leukoplakia-to treat or not to treat. Oral Dis. 2016; 22:494-7.

-Romeo U, Mohsen M, Palaia G, Bellisario A, Del Vecchio A, Tenore G. CO2 laser ablation of oral leukoplakia: with or without extension of margins? Clin Ter. 2020; 171:e209-e215.

-Harifa A, Oakley AM. Carcinoma, Intraepidermal (Squamous Cell Carcinoma in Situ). 2018 Feb 15. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan.

-Nagakeerthana S, Rajesh G, Madhavi S, Karthikeyan K. Bowen’s disease: Two case reports of a giant and dwarf lesions. J Cancer Res Ther. 2017; 13:371-373.

-Sakamoto J, Shigehara K, Shimizu K, Maeda S, Nakagawa T, Kawaguchi S, Izumi K, Kadono Y, Mizokami A. Human papillomavirus 16-positive penile Bowen’s disease involving the distal urethra: A case report. SAGE Open Med Case Rep. 2020 May 13;8:2050313X20918985.

-Aguayo R; Soria X; Abal L; Sanmartín V; Martí RM; Baradad M; Velasco A; Egido R; Gatius S; Casanova JM. Bowen’s Disease Associated with Human Papillomavirus Infection of the Nail Bed. Dermatol Surg. 2011; 37:116-118; Wollina U. Bowen’s disease of the nail apparatus: a series of 8 patients and a literature review. Wien Med Wochenschr. 2015; 165:401-5.

-Wollina U. Bowen’s disease of the nail apparatus: a series of 8 patients and a literature review. Wien Med Wochenschr. 2015; 165:401-5.

-Perruchoud DL, Varonier C, Haneke E, Hunger RE, Beltraminelli H, Borradori L, Ehnis Pérez A. Bowen disease of the nail unit: a retrospective study of 12 cases and their association with human papillomaviruses. J Eur Acad Dermatol Venereol. 2016; 30:1503-6.

-Vivan MM, Hirata SH, Nascimento LS, Enokihara MM. A case of pigmented Bowen’s disease. An Bras Dermatol. 2017; 92:124-125.

-Mota AN, Piñeiro-Maceira J, Alves Mde F, Tarazona MJ. Pigmented Bowen’s disease. An Bras Dermatol. 2014; 89:825-7.

-Cameron A, Rosendahl C, Tschandl P, Riedl E, Kittler H. Dermatoscopy of pigmented Bowen’s disease. J Am Acad Dermatol. 2010; 62:597-604.

-Lellis RF, Veasey JV, Gonçalves RDJ. Pigmented Bowen’s disease associated with high-risk HPV simulating melanoma of the hand. An Bras Dermatol. 2017; 92:686-688.

-Wozniak-Rito AM, Rudnicka L. Bowen’s Disease in Dermoscopy. Acta Dermatovenerol Croat. 2018; 26:157-161.

-Chan SL, Watchorn RE, Panagou E, Panou E, Ong EL, Heelan K, Haider A, Freeman A, Bunker CB. Dermatoscopic findings of penile intraepithelial neoplasia: Bowenoid papulosis, Bowen disease and erythroplasia of Queyrat. Australas J Dermatol. 2019; 60:e201-e207.

-Zalaudek I, Argenziano G, Leinweber B, Citarella L, Hofmann-Wellenhof R, Malvehy J, Puig S, Pizzichetta MA, Thomas L, Soyer HP, Kerl H. Dermoscopy of Bowen’s disease. Br J Dermatol. 2004; 150:1112-6.

-Yang Y, Lin J, Fang S, Han S, Song Z. What’s new in dermoscopy of Bowen’s disease: two new dermoscopic signs and its differential diagnosis. Int J Dermatol. 2017; 56:1022-1025.

-Wu MF, Lv T, Wang HW. Successful treatment for multiple Bowen’s disease using photodynamic therapy: A case report. Photodiagnosis Photodyn Ther. 2020:101783.

-Nanz L, Keim U, Katalinic A, Meyer T, Garbe C, Leiter U. Epidemiology of keratinocyte skin cancer with a Focus on Cutaneous Squamous Cell Carcinoma. Cancers (Basel). 2024;16(3):606.

-Stonesifer CJ, Djavid AR, Grimes JM, Khaleel AE, Soliman YS, Maisel-Campbell A, Garcia-Saleem TJ, Geskin LJ, Carvajal RD. Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. Front Oncol. 2021; 11:734354.

–Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014; 810:120-40.

–Tang H, Fu S, Zhai S, Song Y, Asgari MM, Han J. Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2018; 27:279-288.

–Arafa A, Mostafa A, Navarini AA, Dong JY. The association between smoking and risk of skin cancer: a meta-analysis of cohort studies. Cancer Causes Control. 2020. doi: 10.1007/s10552-020-01319-8.

-Liu-Smith F, Jia J, Zheng Y. UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer. Adv Exp Med Biol. 2017; 996:27-40.

-Liyanage UE, Law MH, Han X, An J, Ong JS, Gharahkhani P, Gordon S, Neale RE, Olsen CM; 23andMe Research Team, MacGregor S, Whiteman DC. Combined analysis of keratinocyte cancers identifies novel genome-wide loci. Hum Mol Genet. 2019; 28:3148-3160.

-Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015; 151:1081-6.

–Firnhaber JM. Diagnosis and treatment of Basal cell and squamous cell carcinoma. Am Fam Physician. 2012; 86:161-8.

-Wakkee M, van Egmond S, Louwman M, Bindels P, van der Lei J, Nijsten T, Hollestein L. Opportunities for improving the efficiency of keratinocyte carcinoma care in primary and specialist care: Results from population-based Dutch cohort studies. Eur J Cancer. 2019; 117:32-40.

-Mendez BM, Thornton JF. Current Basal and Squamous Cell Skin Cancer Management. Plast Reconstr Surg. 2018; 142:373e-387e.

-Archibald LK, Ascha MS, Bordeaux JS. Why it’s hard to see a dermatologist for a skin exam: the patient perspective. Arch Dermatol Res. 2020. doi: 10.1007/s00403-020-02080-3).

-Gharzai LA, Mierzwa ML. Radiotherapy in Cutaneous Squamous Cell and Basal Cell Carcinoma. Facial Plast Surg. 2020; 36:180-185.

-Cameron MC, Lee E, Hibler B, Barker CA, Mori S, Cordova M, Nehal KS, Rossi AM. Basal Cell Carcinoma: Part 1. J Am Acad Dermatol. 2018. pii: S0190-9622(18)30775-8.

-García-de-la-Fuente MR, Santacana M, Vilardell F, Pujol RM, Gari E, Casanova JM. Vulvar Basal Cell Carcinoma: Four Case Reports With Immunohistochemical Study. J Cutan Med Surg. 2017; 21:457‐459.

-García-de-la-Fuente MR, Santacana M, Valls J, Vilardell F, Fernández Armenteros JM, Pujol R, Gari E, Casanova JM. Cytokeratin Profile of Basal Cell Carcinomas According to the Degree of Sun Exposure and to the Anatomical Localization. Am J Dermatopathol. 2018; 40:342‐348.

–Millán-Cayetano JF, Blázquez-Sánchez N, Fernández-Canedo I, Repiso-Jiménez JB, Fúnez-Liébana R, Bautista MD, de Troya-Martin, M. Metastatic Basal Cell Carcinoma: Case Report and Review of the Literature. Indian J Dermatol. 2020; 65:61‐64.

-Aguayo R. “Caracterització de les alteracions moleculars dels carcinomes basocel·lulars esporàdics”. Tesis doctoral. Universitat de Lleida. 2013.

-Chinem VP, Miot HA. Epidemiology of basal cell carcinoma. An Bras Dermatol. 2011; 86:292‐305.

-Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, Neha KS, Rossi AM. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019; 80(2):303-317.

-Pacholczyk M, Czernicki J, Ferenc T. Wpływ słonecznego promieniowania ultrafioletowego (UV) na powstawanie raków skóry. Med Pr. 2016; 67:255‐266.

-Maturo MG, Rachakonda S, Heidenreich B, Pellegrini C, Srinivas N, Requena C, Serra-Guillen C, Llombart B, Sanmartin O, Guillen C, Di Nardo L, Peris K, Fargnoli MC, Nagore E, Kumar R. Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma. Sci Rep. 2020;10(1):8005.

-Segerbäck D, Strozyk M, Snellman E, Hemminki K. Repair of UV dimers in skin DNA of patients with basal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2008; 17:2388-92.

-Capasso A, Viggiano D, Lee MW, Palladino G, Bilancio G, Simeoni M, Capolongo G, Secondulfo C, Ronchi A, Caputo A, Zeppa P, Franco R. Kidney Transplant Modifies the Architecture and Microenvironment of Basal Cell Carcinomas. Kidney Blood Press Res. 2020; 45:368-377.

-Palacios-Álvarez I, González-Sarmiento R, Fernández-López E. Síndrome de Gorlin. Actas Dermosifiliogr. 2018; 109:207‐217.

-Valenzuela-Oñate CA, Magdaleno-Tapial J, Garcia-Legaz Martínez M, Perez-Pastor G, Sanchez Carazo JL. Drug holiday approach for Vismodegib treatment in patients with nevoid basal cell carcinoma syndrome: Three cases from real clinical practice. Dermatol Ther. 2020:e13540.

-Bartoš V, Kullová M. Basal cell carcinoma of the skin with mixed histomorphology: a comparative study. Cesk Patol. 2016; 52:222-226.

-Stanoszek LM, Wang GY, Harms PW. Histologic Mimics of Basal Cell Carcinoma. Arch Pathol Lab Med. 2017; 141:1490-1502.

-Lallas A, Apalla Z, Ioannides D, Argenziano G, Castagnetti F, Moscarella E, Longo C Palmieri T, Ramundo D, Zalaudek I. Dermoscopy in the diagnosis and management of basal cell carcinoma. Future Oncol. 2015; 11:2975-84.

-Emiroglu N, Cengiz FP, Kemeriz F. The relation between dermoscopy and histopathology of basal cell carcinoma. An Bras Dermatol. 2015; 90:351-6.

-Reiter O, Mimouni I, Dusza S, Halpern AC, Leshem YA, Marghoob AA. Dermoscopic features of basal cell carcinoma and its subtypes: A systematic review. J Am Acad Dermatol. 2019:S0190-9622(19)33008-7.

-Enache AO, Pătrașcu V, Simionescu CE, Ciurea RN, Văduva A, Stoica LE. Dermoscopy Patterns and Histopathological Findings in Nodular Basal Cell Carcinoma-Study on 68 Cases. Curr Health Sci J. 2019; 45:116-122.

-Conforti C, Pizzichetta MA, Vichi S, Toffolutti F, Serraino D, Di Meo N, Giuffrida R, Deinlein T, Giacomel J, Rosendahl C, Gourhant JY, Zalaudek I. Sclerodermiform basal cell carcinomas versus other histotypes: analysis of specific demographic, clinical and dermatoscopic features. J Eur Acad Dermatol Venereol. 2020. doi: 10.1111/jdv.16597.

-Wojtowicz I, Żychowska M. Dermoscopy of Basal Cell Carcinoma Part 1: Dermoscopic Findings and Diagnostic Accuracy-A Systematic Literature Review. Cancers (Basel). 2025; 17(3):493.

-Navarrete-Dechent C, Liopyris K, Rishpon A, Marghoob NG, Cordova M, Dusza SW, Sahu A, Kose K, Oliviero M, Rabinovitz H, Busam KJ, Marchetti MA, Chen CJ, Marghoob AA. Association of Multiple Aggregated Yellow-White Globules With Nonpigmented Basal Cell Carcinoma. JAMA Dermatol. 2020. doi: 10.1001/jamadermatol.2020.1450.

-Frerich B, Prall F. Basalzellkarzinom der Gesichts- und Kopfhaut. Update der Therapieverfahren. Pathologe. 2018; 39:457-472.

–Tanese K. Diagnosis and Management of Basal Cell Carcinoma. Curr Treat Options Oncol. 2019; 20:13.

-Cameron MC, Lee E, Hibler B, Giordano CN, Barker CA, Mori S, Cordova M, Nehal  KS, Rossi AM. Basal Cell Carcinoma, PART II: Contemporary Approaches to Diagnosis, Treatment, and Prevention. J Am Acad Dermatol. 2018. pii: S0190-9622(18)30776-X.

-Newlands C, Currie R, Memon A, Whitaker S, Woolford T Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130:S125-S132.

-Golda N, Hruza G. Mohs Micrographic Surgery. Dermatol Clin. 2023; 41(1):39-47.

-Dika E, Veronesi G, Patrizi A, De Salvo S, Misciali C, Baraldi C, Mussi M, Fabbri E, Tartari F, Lambertini M. It’s time for Mohs: Micrographic surgery for the treatment of high-risk basal cell carcinomas of the head and neck regions. Dermatol Ther. 2020:e13474.

-Cho M, Gordon L, Rembielak A, Woo TC. Utility of radiotherapy for treatment of basal cell carcinoma: a review. Br J Dermatol. 2014; 171:968-73.

-Zaorsky NG, Lee CT, Zhang E, Keith SW, Galloway TJ. Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis. Radiother Oncol. 2017; 125:13-20.

-Olschewski T, Bajor K, Lang B, Lang E, Seegenschmiedt MH. Radiotherapy of basal cell carcinoma of the face and head: Importance of low dose per fraction on long-term outcome. J Dtsch Dermatol Ges. 2006; 4:124-30.

-Caccialanza M, Piccinno R, Cuka E, Alberti Violetti S, Rozza M. Radiotherapy of morphea-type basal cell carcinoma: results in 127 cases. J Eur Acad Dermatol Venereol. 2014; 28:1751-5.

-Niebel D, Sirokay J, Hoffmann F, Fröhlich A, Bieber T, Landsberg J. Clinical Management of Locally Advanced Basal-Cell Carcinomas and Future Therapeutic Directions. Dermatol Ther (Heidelb). 2020. doi: 10.1007/s13555-020-00382-y.

-Cozzani R, Del Aguila R, Carrizo M, Sanchez S, Gonzalez A; ML29740 Investigators. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina. Int J Dermatol. 2020; 59:627-632.

–Villani A, Fabbrocini G, Costa C, Scalvenzi M. Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma. Dermatol Ther (Heidelb). 2020; 10:401-412.

-Villani A, Cappello M, Costa C, Fabbrocini G, Scalvenzi M. Advanced basal cell carcinoma treated with vismodegib: impact on the lives of patients and their families. Clin Exp Dermatol. 2020. doi: 10.1111/ced.14287.

-Patrinely JR Jr, Dewan AK, Johnson DB. The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. BioDrugs. 2020. doi: 10.1007/s40259-020-00428-9.

-Wilken R, Criscito M, Pavlick AC, Stevenson ML, Carucci JA. Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer. Facial Plast Surg. 2020; 36:200-210.

–Parekh V, Seykora JT. Cutaneous Squamous Cell Carcinoma. Clin Lab Med. 2017; 37:503-525.

-Waldman A, Schmults C. Cutaneous Squamous Cell Carcinoma. Hematol Oncol Clin North Am. 2019; 33:1-12.

-Dessinioti C, Pitoulias M, Stratigos AJ. Epidemiology of advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol
2022;36(1):39-50.

-Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019; 5:1749-68.

–Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust. 2006; 184:6-10.

-Stang A, Khil L, Kajüter H, Pandeya N, Schmults CD, Ruiz ES, Karia PS, Green AC. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents. J Eur Acad Dermatol Venereol. 2019; 33 Suppl 8(Suppl 8):6-10).

-Vilar-Coromina N, Miró-Queralt J, Cano-Bautista A, Vilardell-Gil L, Torres Babié P, Marcos-Gragera R. Cáncer cutáneo distinto de melanoma: tendencia de la incidencia poblacional en Girona, 1994-2007. Med Clin (Barc). 2011; 137:145-51).

-Oh CM, Cho H, Won YJ, Kong HJ, Roh YH, Jeong KH, Jung KW. Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea. Cancer Res Treat. 2018; 50:729-737.

–Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol. 1997; 133:735-40.

-Martín García E, Arias-Santiago S, Serrano-Ortega S, Buendía-Eisman A. Changes in the Incidence of Skin and Lip Cancer Between 1978 and 2007. Actas Dermosifiliogr. 2017; 108:335-345.

-Serna-Higuita LM, Harrison SL, Buttner P, Glasby M, Raasch BA, Iftner A, Garbe C, Martus P, Iftner T. Modifiable Risk-factors for Keratinocyte Cancers in Australia: A Case-control Study. Acta Derm Venereol. 2019; 99:404-411.

–Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, Brash DE. Sunburn and p53 in the onset of skin cancer. Nature. 1994; 372(6508):773-6.

-Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. 1996; 1:136-42.

-Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet J Rare Dis. 2011; 6:70.

-Moriwaki S, Kanda F, Hayashi M, Yamashita D, Sakai Y, Nishigori C; Xeroderma pigmentosum clinical practice guidelines revision committee. Xeroderma pigmentosum clinical practice guidelines. J Dermatol. 2017; 44:1087-1096.

-O’Sullivan DE, Brenner DR, Demers PA, Villeneuve PJ, Friedenreich CM, King WD; ComPARe Study Group. Indoor tanning and skin cancer in Canada: A meta-analysis and attributable burden estimation. Cancer Epidemiol. 2019; 59:1-7.

–de Gruijl FR, Rebel H. Early events in UV carcinogénesis -DNA damage, target cells and mutant p53 foci. Photochem Photobiol. 2008; 84:382-387.

-Hofbauer G. Phototherapie und Karzinogenese. Hautarzt. 2013; 64:349-53.

-Ortiz-Salvador JM, Ferrer DS, Saneleuterio-Temporal M, Victoria Martínez AM, Ferriols AP, Vilata Corell JJ, Alegre de Miquel V. Photocarcinogenic Risk Associated With Narrowband UV-B Phototherapy: An Epidemiologic Study in a Tertiary Care Hospital. Actas Dermosifiliogr. 2018; 109:340-345.

-Thompson KG, Kim N. Distinguishing Myth from Fact: Photocarcinogenesis and Phototherapy. Dermatol Clin. 2020; 38:25-35.

-Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne JP, Richard MA. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 3:22-31.

–Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003; 348:1681-91.

-Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999; 40(2 Pt 1):177-86.

-Garrett GL, Blanc PD, Boscardin J, Lloyd AA, Ahmed RL, Anthony T, Bibee K, Breithaupt A, Cannon J, Chen A, Cheng JY, Chiesa-Fuxench Z, Colegio OR, Curiel-Lewandrowski C, Del Guzzo CA, Disse M, Dowd M, Eilers R Jr, Ortiz AE, Morris C, Golden SK, Graves MS, Griffin JR, Hopkins RS, Huang CC, Bae GH, Jambusaria A, Jennings TA, Jiang SI, Karia PS, Khetarpal S, Kim C, Klintmalm G, Konicke K, Koyfman SA, Lam C, Lee P, Leitenberger JJ, Loh T, Lowenstein S, Madankumar R JF, Nijhawan RI, Ochoa S, Olasz EB, Otchere E, Otley C, Oulton J, Patel PH, Patel VA, Prabhu AV, Pugliano-Mauro M, Schmults CD, Schram S, Shih AF, Shin T, Soon S, Soriano T, Srivastava D, Stein JA, Sternhell-Blackwell K, Taylor S, Vidimos A, Wu P, Zajdel N, Zelac D, Arron ST. Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. JAMA Dermatol. 2017; 153:296-303.

-De Rosa N, Paddon VL, Liu Z, Glanville AR, Parsi K. Nonmelanoma Skin Cancer Frequency and Risk Factors in Australian Heart and Lung Transplant Recipients. JAMA Dermatol. 2019; 155:716-719.

-Euvrard S, Kanitakis J, Pouteil-Noble C, Claudy A, Touraine JL. Skin cancers in organ transplant recipients. Ann Transplant. 1997; 2:28-32.

–Mittal A, Colegio OR. Skin Cancers in Organ Transplant Recipients. Am J Transplant. 2017; 17:2509-2530.

-Euvrard S, Kanitakis J, Cochat P, Claudy A. Skin cancers following pediatric organ transplantation. Dermatol Surg. 2004; 30(4 Pt 2):616-21.

-Huang JT, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Al-Sayegh H, London WB, Marghoob A, Phung TL, Pope E, Gerami P, Schmidt B, Robinson S, Bartenstein D, Bahrani E, Brahmbhatt M, Chen L, Haddock E, Mansour D, Nguyen J, Raisanen T, Tran G, Travis K, Wolner Z, Eichenfield LF. Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. J Pediatr. 2019; 211:152-158.

-Wang JL, Yin WJ, Zhou LY, Zhou G, Liu K, Hu C, Zuo XC, Wang YF. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. Clin Rheumatol. 2020; 39:769-778.

-James LJ, Saglimbene V, Wong G, Tong A, Luu LDW, Craig J, Howard K, Howell M. Behavioural and pharmaceutical interventions for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomised controlled trials. BMJ Open. 2020; 10:e029265.

–Rasmussen CL, Thomsen LT, Aalborg GL, Kjaer SK. Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination. Gynecol Oncol. 2020; 157:664-670.

-Mehra NS, Ho TP, Herrera Hernandez L, Quevedo JF, Costello BA, Pagliaro LC. Penile cancer with visceral metastasis and p16/human papillomavirus positivity: An unusual case of long-term survival. Urol Case Rep. 2020; 33:101278.

-Albuquerque A, Stirrup O, Nathan M, Clifford GM. Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: A systematic review and meta-analysis. Am J Transplant. 2020. doi: 10.1111/ajt.15942.

-Foki E, Gangl K, Kranebitter V, Niederberger-Leppin V, Eckl-Dorna J, Wiebringhaus R, Thurnher D, Heiduschka G. Early effects of cigarette smoke extract on human oral keratinocytes and carcinogenesis in head and neck squamous cell carcinoma. Head Neck. 2020. doi: 10.1002/hed.26247.

-Lechien JR, Descamps G, Seminerio I, Furgiuele S, Dequanter D, Mouawad F, Badoual C, Journe F, Saussez S. HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. Cancers (Basel). 2020; 12:1060

-Ghazawi FM, Lu J, Savin E, Zubarev A, Chauvin P, Sasseville D, Zeitouni A, Litvinov IV. Epidemiology and Patient Distribution of Oral Cavity and Oropharyngeal SCC in Canada. J Cutan Med Surg. 2020:1203475420915448.

-Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, Green AC, Harwood CA, de Koning MN, Naldi L, Nindl I, Pawlita M, Pfister H, Proby CM, Quint WG, ter Schegget J, Waterboer T, Weissenborn S, Feltkamp MC; EPI-HPV-UV-CA group. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res. 2010; 70:9777-86.

-Proby CM, Harwood CA, Neale RE, Green AC, Euvrard S, Naldi L, Tessari G, Feltkamp MC, de Koning MN, Quint WG, Waterboer T, Pawlita M, Weissenborn S, Wieland U, Pfister H, Stockfleth E, Nindl I, Abeni D, Schegget JT, Bouwes Bavinck JN; EPI-HPV-UV-CA group. A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant. 2011; 11:1498-508.

-Chockalingam R, Downing C, Tyring SK. Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients. J Clin Med. 2015; 4:1229-39.

-Borgogna C, Olivero C, Lanfredini S, Calati F, De Andrea M, Zavattaro E, Savoia P, Trisolini E, Boldorini R, Patel GK, Gariglio M. β-HPV Infection Correlates with Early Stages of Carcinogenesis in Skin Tumors and Patient-Derived Xenografts from a Kidney Transplant Recipient Cohort. Front Microbiol. 2018; 9:117.

–Tang H, Fu S, Zhai S, Song Y, Asgari MM, Han J. Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2018; 27:279-288.

-Brash DE. Roles of the transcription factor p53 in keratinocyte carcinomas. Br J Dermatol. 2006; 154(Suppl 1):8-10.

–Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. Cell Cycle. 2015; 14:2355-61.

-Lazo de la Vega L, Bick N, Hu K, Rahrig SE, Silva CD, Matayoshi S, Picciarelli P, Wang X, Sugar A, Soong HK, Mian SI, Robinson DR, Chinnaiyan AM, Demirci H, Daniels AB, Worden F, Eberhart CG, Tomlins SA, Rao RC, Harms PW. Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes. Mod Pathol. 2020. doi: 10.1038/s41379-020-0571-7.

-Fernandez-Figueras MT, Puig L. The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma: Epithelial-to-Mesenchymal Transition in Cutaneous SCC. Curr Treat Options Oncol. 2020; 21:47.

-Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018; 78:237-247.

-Lee KJ, Soyer HP. Cutaneous keratinocyte cancers of the head and neck: Epidemiology, risk factors and clinical, dermoscopic and reflectance confocal microscopic features. Oral Oncol. 2019; 98:109-117.

-Stang A, Wellmann I, Kajüter H, Trocchi P, Becker JC, Green AC, Jöckel KH, Khil L. Differences in site-specific incidence and relative survival of cutaneous and mucocutaneous genital squamous cell carcinoma in Germany, 2007-2015. Int J Cancer. 2020. doi: 10.1002/ijc.33109.

-Rodríguez-Blanco I, Flórez Á, Paredes-Suárez C, Rodríguez-Lojo R, González-Vilas D, Ramírez-Santos A, Paradela S, Suárez Conde I, Pereiro-Ferreirós M. Actinic Cheilitis Prevalence and Risk Factors: A Cross-sectional, Multicentre Study in a Population Aged 45 Years and Over in North-west Spain. Acta Derm Venereol. 2018; 98:970-974).

-Bota JP, Lyons AB, Carroll BT. Squamous Cell Carcinoma of the Lip-A Review of Squamous Cell Carcinogenesis of the Mucosal and Cutaneous Junction. Dermatol Surg. 2017; 43:494-506.

-Dinnes J, Deeks JJ, Chuchu N, Matin RN, Wong KY, Aldridge RB, Durack A, Gulati A, Chan SA, Johnston L, Bayliss SE, Leonardi-Bee J, Takwoingi Y, Davenport C, O’Sullivan C, Tehrani H, Williams HC; Cochrane Skin Cancer Diagnostic Test Accuracy Group. Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev. 2018; 12(12):CD011901.

-Elmas ÖF, Metin MS, Kilitçi A. Dermoscopic Features of Lower Lip Squamous Cell Carcinoma: A Descriptive Study. Indian Dermatol Online J. 2019; 10:536-541; Rosendahl C, Cameron A, Argenziano G, Zalaudek I, Tschandl P, Kittler H. Dermoscopy of squamous cell carcinoma and keratoacanthoma. Arch Dermatol. 2012; 148:1386-92.

-Papageorgiou C, Spyridis I, Manoli SM, Busila I, Nasturica IE, Lallas K, Panagopoulou A, Papadimitriou I, Sideris N, Gentsidi T, Gonzalez-Cuevas R, Ilieva A, Ioannides D, Apalla Z, Lallas A. Accuracy of dermoscopic criteria for the differential diagnosis between irritated seborrheic keratosis and squamous cell carcinoma. J Am Acad Dermatol. 2020:S0190-9622(20)30227-9.

–Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS, Kripke ML, Lippman SM. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005; 23:759-65.

–Stang A, Wellmann I, Kajüter H, Trocchi P, Becker JC, Green AC, Jöckel KH, Khil L. Differences in site-specific incidence and relative survival of cutaneous and mucocutaneous genital squamous cell carcinoma in Germany, 2007-2015. Int J Cancer. 2020. doi: 10.1002/ijc.33109.

-Motaparthi K, Kapil JP, Velazquez EF. Cutaneous Squamous Cell Carcinoma: Review of the Eighth Edition of the American Joint Committee on Cancer Staging Guidelines, Prognostic Factors, and Histopathologic Variants. Adv Anat Pathol. 2017; 24:171-194.

-Skulsky SL, O’Sullivan B, McArdle O, Leader M, Roche M, Conlon PJ, O’Neill JP. Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology. Head Neck. 2017; 39:578-594

-Kofler L. Klassifikation des Plattenepithelkarzinoms der Haut. Wie erkenne ich meinen Hochrisikopatienten?. Hautarzt. 2019; 70:870-874.

-Sood A, Wykes J, Roshan D, Wang LY, McGuinness J, Fowler A, Ebrahimi A. A critical analysis of the prognostic performance of the 8th edition American Joint Committee on Cancer staging for metastatic cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2019; 41:1591-1596.

-Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014; 32:327-34.

-Ruiz ES, Karia PS, Besaw R, Schmults CD. Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2019; 155:819-825.

–Forest VI, Clark JJ, Veness MJ, Milross C. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers. Cancer. 2010; 116:1298-1304.

-O’Bryan K, Sherman W, Niedt GW, Taback B, Manolidis S, Wang A, Ratner D. An evolving paradigm for the workup and management of high-risk cutaneous squamouscell carcinoma. J Am Acad Dermatol. 2013; 69:595-602.

-Sahovaler A, Krishnan RJ, Yeh DH, Zhou Q, Palma D, Fung K, Yoo J, Nichols A, MacNeil SD. Outcomes of Cutaneous Squamous Cell Carcinoma in the Head and Neck Region With Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2019; 145:352-360.

-Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, Dreno B, Fargnoli MC, Forsea AM, Frenard C, Harwood CΑ, Hauschild A, Hoeller C, Kandolf-Sekulovic L, Kaufmann R, Kelleners-Smeets NW, Malvehy J, Del Marmol V, Middleton MR, Moreno-Ramirez D, Pellecani G, Peris K, Saiag P, van den Beuken-van Everdingen MHJ, Vieira R, Zalaudek I, Eggermont AMM, Grob JJ; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer. 2020:S0959-8049(20)30018-6.

-Newlands C, Currie R, Memon A, Whitaker S, Woolford T Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130:S125-S132.

-Ruiz ES, Karia PS, Morgan FC, Schmults CD. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol. 2017; 76:217-225.

-Maher JM, Schmults CD, Murad F, Karia PS, Benson CB, Ruiz ES. Detection of subclinical disease with baseline and surveillance imaging in high-risk cutaneous squamous cell carcinomas. J Am Acad Dermatol. 2020; 82:920‐926.

-Kofler L, Kofler K, Schulz C, Breuninger H, Häfner HM. Sentinel lymph node biopsy for high-thickness cutaneous squamous cell carcinoma. Arch Dermatol Res. 2020. doi: 10.1007/s00403-020-02082-1.

-Maubec E. Update of the Management of Cutaneous Squamous-cell Carcinoma. Acta Derm Venereol. 2020; 100:adv00143. doi: 10.2340/00015555-3498.

-Kallini JR, Hamed N, Khachemoune A. Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. Int J Dermatol. 2015; 54:130-40.

-Potenza C, Bernardini N, Balduzzi V, Losco L, Mambrin A, Marchesiello A, Tolino E, Zuber S, Skroza N, Proietti I. A Review of the Literature of Surgical and Nonsurgical Treatments of Invasive Squamous Cells Carcinoma. Biomed Res Int. 2018; 2018:9489163.

-Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, Dreno B, Concetta Fargnoli M, Forsea AM, Frenard C, Harwood CA, Hauschild A, Hoeller C, Kandolf-Sekulovic L, Kaufmann R, Kelleners-Smeets NWJ, Malvehy J, Del Marmol V, Middleton MR, Moreno-Ramirez D, Pellecani G, Peris K, Saiag P, van den Beuken-van Everdingen MHJ, Vieira R, Zalaudek I, Eggermont AMM, Grob JJ; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020:S0959-8049(20)30019-8.

-Svensson H, Paoli J. Clinicopathological Factors Associated with Incomplete Excision of Cutaneous Squamous Cell Carcinoma. Acta Derm Venereol. 2020. doi: 10.2340/00015555-3532.

-Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. J Am Acad Dermatol. 2018; 78:249-261.

-Cañueto J, Jaka A, Toll A. The Value of Adjuvant Radiotherapy in Cutaneous Squamous Cell Carcinoma: A Review. Actas Dermosifiliogr. 2018; 109:476-484; Maubec E. Update of the Management of Cutaneous Squamous-cell Carcinoma. Acta Derm Venereol. 2020; 100:adv00143. doi: 10.2340/00015555-3498.

-Burton KA, Ashack KA, Khachemoune A. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin Dermatol. 2016; 17:491-508.

-Jarkowski A 3rd, Hare R, Loud P, Skitzki JJ, Kane JM 3rd, May KS, Zeitouni NC, Nestico J, Vona KL, Groman A, Khushalani NI. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature. Am J Clin Oncol. 2016; 39:545-548.

-Behshad R, Garcia-Zuazaga J, Bordeaux JS. Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: a review of the literature. Br J Dermatol. 2011; 165:1169-77.

-Galbiati D, Cavalieri S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Platini F, Locati L, Giacomelli L, Licitra L, Bossi P. Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. Drugs Context. 2019; 8:212611. doi: 10.7573/dic.212611.

-Cowey CL, Robert NJ, Espirito JL, Davies K, Frytak J, Lowy I, Fury MG. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy. Cancer Med. 2020. doi: 10.1002/cam4.3146).

-Dessinioti C, Stratigos AJ. Overview of guideline recommendations for the management of high-risk and advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2022; 36 Suppl 1:11-18.

-Newman JG, Hall MA, Kurley SJ, Cook RW, Farberg AS, Geiger JL, Koyfman SA. Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review. Head Neck. 2021; 43(9):2822-2843.

-Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012; 18(5):1435-46).

-Ribero S, Stucci LS, Daniels GA, Borradori L. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence? Curr Opin Oncol. 2017; 29:129-135.

-Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020; 8:e000775.

-Desilets A, Soulières D. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma. Expert Opin Drug Saf. 2020; 11:1-7.

-Zech HB, Laban S, Schafhausen P, Bussmann L, Betz C, Busch CJ. Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs. Highlights des ASCO-Meetings 2019. HNO. 2019; 67:898-904.

-Fujimura T, Kambayashi Y, Tono H, Chinbing L, Ohuchi K, Hashimoto A, Aiba S. Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy. Dermatol Ther. 2020. doi: 10.1111/dth.13672.

-Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance A, Grange F, Meyer N, Joshi A, Billan S, Zhang P, Gumuscu B, Swaby RF, Grob JJ. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. 2021; 32(10):1276-1285.

-Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Thai AA, Stankevich E, Booth J, Yoo SY, Li S, Chen Z, Okoye E, Chen CI, Mastey V, Sasane M, Lowy I, Fury MG, Migden MR. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021; 9(8):e002757.

-Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2022; 387(17):1557-1568.

–Chang MS, Azin M, Demehri S. Cutaneous Squamous Cell Carcinoma: The Frontier of Cancer Immunoprevention. Annu Rev Pathol. 2022; 17:101-119.

-Ramchatesingh B, Martínez Villarreal A, Arcuri D, Lagacé F, Setah SA, Touma F, Al-Badarin F, Litvinov IV. The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review. Int J Mol Sci. 2022; 23(20):12622.

-Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 2012; 118(8):2128-37.